W

Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871

Watchlist Manager
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Watchlist
Price: 11.71 CNY -0.26%
Market Cap: 1.9B CNY
Have any thoughts about
Wuhan Hvsen Biotechnology Co Ltd?
Write Note

Wuhan Hvsen Biotechnology Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Wuhan Hvsen Biotechnology Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
W
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Capital Expenditures
-ÂĄ184.3m
CAGR 3-Years
7%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Capital Expenditures
-ÂĄ219.6m
CAGR 3-Years
46%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Capital Expenditures
-ÂĄ103.9m
CAGR 3-Years
30%
CAGR 5-Years
-5%
CAGR 10-Years
-2%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Capital Expenditures
-ÂĄ1.6B
CAGR 3-Years
-3%
CAGR 5-Years
-27%
CAGR 10-Years
-23%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Capital Expenditures
-ÂĄ632.5m
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
-24%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Capital Expenditures
-ÂĄ81.9m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Wuhan Hvsen Biotechnology Co Ltd
Glance View

Market Cap
1.9B CNY
Industry
Pharmaceuticals

HVSEN Biotechnology Co., Ltd. engages in the research and development, production, and sale of veterinary drugs. The company is headquartered in Wuhan, Hubei and currently employs 828 full-time employees. The company went IPO on 2020-08-24. The Company’s main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The firm mainly conducts its businesses in the China market.

Intrinsic Value
22.35 CNY
Undervaluation 48%
Intrinsic Value
Price
W

See Also

What is Wuhan Hvsen Biotechnology Co Ltd's Capital Expenditures?
Capital Expenditures
-184.3m CNY

Based on the financial report for Dec 31, 2023, Wuhan Hvsen Biotechnology Co Ltd's Capital Expenditures amounts to -184.3m CNY.

What is Wuhan Hvsen Biotechnology Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-40%

Over the last year, the Capital Expenditures growth was 57%. The average annual Capital Expenditures growth rates for Wuhan Hvsen Biotechnology Co Ltd have been 7% over the past three years , -40% over the past five years .

Back to Top